{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:08:44Z","timestamp":1792372124012,"version":"4.4.0"},"reference-count":161,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,11,8]],"date-time":"2017-11-08T00:00:00Z","timestamp":1510099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SPP1463 FL345\/4-2"],"award-info":[{"award-number":["SPP1463 FL345\/4-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC992-C05"],"award-info":[{"award-number":["CRC992-C05"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC 992-C04"],"award-info":[{"award-number":["CRC 992-C04"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.semcancer.2017.10.011","type":"journal-article","created":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T23:02:15Z","timestamp":1510268535000},"page":"68-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia"],"prefix":"10.1016","volume":"51","author":[{"given":"Christian","family":"Flotho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"L\u00fcbbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.semcancer.2017.10.011_bib0005","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.semcancer.2017.10.011_bib0010","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/ng.391","article-title":"Acquired mutations in TET2 are common in myelodysplastic syndromes","volume":"41","author":"Langemeijer","year":"2009","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.semcancer.2017.10.011_bib0015","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2010.31.1175","article-title":"Unraveling the molecular pathophysiology of myelodysplastic syndromes","volume":"29","author":"Bejar","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.semcancer.2017.10.011_bib0020","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.semcancer.2017.10.011_bib0025","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.semcancer.2017.10.011_bib0030","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/leu.2011.232","article-title":"SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts","volume":"26","author":"Visconte","year":"2012","journal-title":"Leukemia"},{"issue":"7367","key":"10.1016\/j.semcancer.2017.10.011_bib0035","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.semcancer.2017.10.011_bib0040","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/ng.1031","article-title":"Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes","volume":"44","author":"Graubert","year":"2011","journal-title":"Nat. Genet."},{"issue":"12","key":"10.1016\/j.semcancer.2017.10.011_bib0045","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","article-title":"Clonal architecture of secondary acute myeloid leukemia","volume":"366","author":"Walter","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.semcancer.2017.10.011_bib0050","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/leu.2013.58","article-title":"Clonal diversity of recurrently mutated genes in myelodysplastic syndromes","volume":"27","author":"Walter","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.semcancer.2017.10.011_bib0055","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ng.2413","article-title":"Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis","volume":"44","author":"Busque","year":"2012","journal-title":"Nat. Genet ."},{"issue":"26","key":"10.1016\/j.semcancer.2017.10.011_bib0060","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.semcancer.2017.10.011_bib0065","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat. Med."},{"issue":"26","key":"10.1016\/j.semcancer.2017.10.011_bib0070","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.semcancer.2017.10.011_bib0075","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.semcancer.2017.10.011_bib0080","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2141.2009.07697.x","article-title":"Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia","volume":"145","author":"Gelsi-Boyer","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"25","key":"10.1016\/j.semcancer.2017.10.011_bib0085","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMoa1005143","article-title":"DNMT3A mutations in acute myeloid leukemia","volume":"363","author":"Ley","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2017.10.011_bib0090","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0092-8674(80)90237-8","article-title":"Cellular differentiation, cytidine analogs and DNA methylation","volume":"20","author":"Jones","year":"1980","journal-title":"Cell"},{"issue":"6990","key":"10.1016\/j.semcancer.2017.10.011_bib0095","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature02625","article-title":"Epigenetics in human disease and prospects for epigenetic therapy","volume":"429","author":"Egger","year":"2004","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.semcancer.2017.10.011_bib0100","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrd1698","article-title":"Azacitidine","volume":"4","author":"Issa","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.semcancer.2017.10.011_bib0105","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nrd2180","article-title":"Decitabine","volume":"5","author":"Gore","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.semcancer.2017.10.011_bib0110","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nrg.2016.93","article-title":"Targeting the cancer epigenome for therapy","volume":"17","author":"Jones","year":"2016","journal-title":"Nat. Rev. Genet."},{"issue":"7","key":"10.1016\/j.semcancer.2017.10.011_bib0115","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.leukres.2010.02.004","article-title":"The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer\/testis antigens in myeloid leukemia cells","volume":"34","author":"Almstedt","year":"2010","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.semcancer.2017.10.011_bib0120","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.semcancer.2017.10.011_bib0125","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-Demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.semcancer.2017.10.011_bib0130","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/ng.3889","article-title":"DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats","volume":"49","author":"Brocks","year":"2017","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.semcancer.2017.10.011_bib0135","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2017.10.011_bib0140","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2017.10.011_bib0145","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2017.10.011_bib0150","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.semcancer.2017.10.011_bib0155","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.semcancer.2017.10.011_bib0160","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"L\u00fcbbert","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2017.10.011_bib0165","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","article-title":"Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.semcancer.2017.10.011_bib0170","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1200\/JCO.2008.19.6550","article-title":"Multicenter study of decitabine administered daily for 5\u2009days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial","volume":"27","author":"Steensma","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.semcancer.2017.10.011_bib0175","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","article-title":"Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia","volume":"28","author":"Cashen","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.semcancer.2017.10.011_bib0180","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3324\/haematol.2011.048231","article-title":"A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy","volume":"97","author":"L\u00fcbbert","year":"2012","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.semcancer.2017.10.011_bib0185","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2017.10.011_bib0190","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1200\/JCO.2007.15.4245","article-title":"Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group","volume":"27","author":"B\u00fcchner","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2017.10.011_bib0195","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1038\/bcj.2014.10","article-title":"Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience","volume":"4","author":"Lazarevic","year":"2014","journal-title":"Blood Cancer J."},{"issue":"9","key":"10.1016\/j.semcancer.2017.10.011_bib0200","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/bmt.2009.64","article-title":"Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS\/AML patients","volume":"44","author":"L\u00fcbbert","year":"2009","journal-title":"Bone Marrow Transplant."},{"issue":"11","key":"10.1016\/j.semcancer.2017.10.011_bib0205","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/bmt.2008.400","article-title":"Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome","volume":"43","author":"De Padua Silva","year":"2009","journal-title":"Bone Marrow Transplant."},{"issue":"6","key":"10.1016\/j.semcancer.2017.10.011_bib0210","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1200\/JCO.2012.46.4222","article-title":"When azanucleoside treatment can be curative: nonintensive bridging strategy before allografting in older patients with myelodysplastic syndrome\/acute myeloid leukemia","volume":"31","author":"L\u00fcbbert","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"36","key":"10.1016\/j.semcancer.2017.10.011_bib0215","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1200\/JCO.2012.44.3499","article-title":"Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies","volume":"30","author":"Damaj","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.semcancer.2017.10.011_bib0220","doi-asserted-by":"crossref","first-page":"12342","DOI":"10.18632\/oncotarget.12511","article-title":"Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts","volume":"8","author":"Yahng","year":"2017","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.semcancer.2017.10.011_bib0225","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1182\/blood-2007-03-082404","article-title":"New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients","volume":"110","author":"Haase","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semcancer.2017.10.011_bib0230","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/leu.2008.173","article-title":"TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis","volume":"23","author":"Bowen","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.semcancer.2017.10.011_bib0235","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"R\u00fccker","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.semcancer.2017.10.011_bib0240","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1182\/blood-2011-07-367508","article-title":"Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies","volume":"119","author":"Kayser","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.semcancer.2017.10.011_bib0245","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.semcancer.2017.10.011_bib0250","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00277-015-2547-0","article-title":"Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group","volume":"95","author":"L\u00fcbbert","year":"2016","journal-title":"Ann. Hematol."},{"issue":"21","key":"10.1016\/j.semcancer.2017.10.011_bib0255","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.semcancer.2017.10.011_bib0260","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.leukres.2006.03.003","article-title":"Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine","volume":"31","author":"Graef","year":"2007","journal-title":"Leuk. Res."},{"issue":"9","key":"10.1016\/j.semcancer.2017.10.011_bib0265","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/cncr.24198","article-title":"Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia","volume":"115","author":"Jabbour","year":"2009","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.semcancer.2017.10.011_bib0270","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/bmt.2009.222","article-title":"Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting","volume":"45","author":"L\u00fcbbert","year":"2010","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"10.1016\/j.semcancer.2017.10.011_bib0275","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/bmt.2009.266","article-title":"5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis","volume":"45","author":"Czibere","year":"2010","journal-title":"Bone Marrow Transplant."},{"issue":"6","key":"10.1016\/j.semcancer.2017.10.011_bib0280","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/leu.2013.7","article-title":"Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation","volume":"27","author":"Schroeder","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.semcancer.2017.10.011_bib0285","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/bmt.2015.10","article-title":"5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft","volume":"50","author":"Steinmann","year":"2015","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"10.1016\/j.semcancer.2017.10.011_bib0290","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bbmt.2014.12.016","article-title":"Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions\u2013a retrospective multicenter analysis from the German Cooperative Transplant Study Group","volume":"21","author":"Schroeder","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"7","key":"10.1016\/j.semcancer.2017.10.011_bib0295","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3324\/haematol.2015.140996","article-title":"Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia","volume":"101","author":"Craddock","year":"2016","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.semcancer.2017.10.011_bib0300","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/bmt.2011.210","article-title":"Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT","volume":"47","author":"Singh","year":"2012","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.semcancer.2017.10.011_bib0305","first-page":"280","article-title":"Decitabine+ CAG +DLI in relapsed acute myeloid leukemia after allogeneic stem cell transplantation","volume":"21","author":"Wang","year":"2016","journal-title":"J. BUON"},{"issue":"4","key":"10.1016\/j.semcancer.2017.10.011_bib0310","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00277-012-1607-y","article-title":"Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT)","volume":"92","author":"Ganguly","year":"2013","journal-title":"Ann. Hematol."},{"issue":"22","key":"10.1016\/j.semcancer.2017.10.011_bib0315","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1182\/blood.V128.22.3446.3446","article-title":"Decitabine As salvage therapy for relapse of AML and MDS after allogeneic stem cell Transplantation\u2013a retrospective multicenter analysis on behalf of the german cooperative transplant study group","volume":"128","author":"Schroeder","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.semcancer.2017.10.011_bib0320","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1182\/blood.V128.22.2247.2247","article-title":"Decitabine (DAC) in combination with donor lymphocyte infusions (DLIs) can induce remissions of overt aml relapses after allogeneic transplantation","volume":"128","author":"Sommer","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semcancer.2017.10.011_bib0325","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2011-08-375840","article-title":"Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation","volume":"119","author":"Schmid","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semcancer.2017.10.011_bib0330","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2009-12-257253","article-title":"In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia","volume":"116","author":"Choi","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semcancer.2017.10.011_bib0335","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2009-03-210393","article-title":"Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting","volume":"115","author":"Sanchez-Abarca","year":"2010","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.semcancer.2017.10.011_bib0340","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","article-title":"Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)","volume":"119","author":"Goodyear","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.semcancer.2017.10.011_bib0345","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/leu.2013.64","article-title":"Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation","volume":"27","author":"Schroeder","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.semcancer.2017.10.011_bib0350","doi-asserted-by":"crossref","first-page":"e1314425","DOI":"10.1080\/2162402X.2017.1314425","article-title":"Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects","volume":"6","author":"Ehx","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.semcancer.2017.10.011_bib0355","series-title":"Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Biological and Therapeutic Continuum","first-page":"203","article-title":"A pediatric perspective on myelodysplastic syndromes","author":"Flotho","year":"2014"},{"issue":"3","key":"10.1016\/j.semcancer.2017.10.011_bib0360","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/leu.2010.297","article-title":"Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study","volume":"25","author":"Strahm","year":"2011","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.semcancer.2017.10.011_bib0365","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/bjh.13915","article-title":"Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group","volume":"172","author":"Cseh","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.semcancer.2017.10.011_bib0370","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3324\/haematol.2016.145821","article-title":"Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation","volume":"101","author":"Waespe","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2017.10.011_bib0375","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.semcancer.2017.10.011_bib0380","series-title":"Childhood Leukemias","first-page":"444","article-title":"Chronic myeloproliferative disorders","author":"Niemeyer","year":"2012"},{"issue":"7","key":"10.1016\/j.semcancer.2017.10.011_bib0385","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1182\/blood-2014-08-550483","article-title":"How I treat juvenile myelomonocytic leukemia","volume":"125","author":"Locatelli","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.semcancer.2017.10.011_bib0390","first-page":"1569","article-title":"Childhood myelodysplastic syndrome in Denmark: incidence and predisposing conditions","volume":"9","author":"Hasle","year":"1995","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.semcancer.2017.10.011_bib0395","first-page":"3534","article-title":"Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases","volume":"89","author":"Niemeyer","year":"1997","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semcancer.2017.10.011_bib0400","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/blood.V91.1.365","article-title":"Differentiating juvenile myelomonocytic leukemia from infectious disease","volume":"91","author":"Niemeyer","year":"1998","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.semcancer.2017.10.011_bib0405","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/01.mph.0000140653.50344.5c","article-title":"Viral infections in juvenile myelomonocytic leukemia: prevalence and clinical implications","volume":"26","author":"Manabe","year":"2004","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2017.10.011_bib0410","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/MPH.0b013e31819ed260","article-title":"Morphologic differential diagnosis of juvenile myelomonocytic leukemia?pitfalls apart from viral infection","volume":"31","author":"Karow","year":"2009","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.semcancer.2017.10.011_bib0415","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3324\/haematol.2014.114595","article-title":"RAS diseases in children","volume":"99","author":"Niemeyer","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.semcancer.2017.10.011_bib0420","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/sj.leu.2401240","article-title":"RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML)","volume":"13","author":"Flotho","year":"1999","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.semcancer.2017.10.011_bib0425","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng1156","article-title":"Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia","volume":"34","author":"Tartaglia","year":"2003","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.semcancer.2017.10.011_bib0430","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3324\/haematol.2009.010355","article-title":"Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia (JMML) and neurofibromatosis type 1","volume":"95","author":"Steinemann","year":"2010","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.semcancer.2017.10.011_bib0435","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/ng.641","article-title":"Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia","volume":"42","author":"Niemeyer","year":"2010","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.semcancer.2017.10.011_bib0440","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1182\/blood.V93.2.459","article-title":"Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients","volume":"93","author":"Luna-Fineman","year":"1999","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semcancer.2017.10.011_bib0445","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2004-05-1944","article-title":"Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS\/EBMT trial","volume":"105","author":"Locatelli","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semcancer.2017.10.011_bib0450","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/1097-0142(1984)54:4<675::AID-CNCR2820540415>3.0.CO;2-Q","article-title":"Subacute and chronic myelomonocytic leukemia in children (juvenile CML). Clinical and hematologic observations, and identification of prognostic factors","volume":"54","author":"Castro-Malaspina","year":"1984","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.semcancer.2017.10.011_bib0455","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/pbc.21038","article-title":"Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria","volume":"49","author":"Bergstr\u00e4sser","year":"2007","journal-title":"Pediatr. Blood Cancer"},{"issue":"25","key":"10.1016\/j.semcancer.2017.10.011_bib0460","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJM199412223312503","article-title":"A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia","volume":"331","author":"Castleberry","year":"1994","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.semcancer.2017.10.011_bib0465","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.V88.7.2634.bloodjournal8872634","article-title":"Inhibition of proliferation and induction of apoptosis in juvenile myelomonocytic leukemic cells by the granulocyte-macrophage colony-stimulating factor analogue E21R","volume":"88","author":"Iversen","year":"1996","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.semcancer.2017.10.011_bib0470","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1182\/blood.V99.11.4147","article-title":"Targeting Raf-1 gene expression by a DNA enzyme inhibits juvenile myelomonocytic leukemia cell growth","volume":"99","author":"Iversen","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semcancer.2017.10.011_bib0475","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/pbc.25342","article-title":"Phase II\/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group","volume":"62","author":"Stieglitz","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2017.10.011_bib0480","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.leukres.2008.08.022","article-title":"Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium","volume":"33","author":"Chan","year":"2009","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.semcancer.2017.10.011_bib0485","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3324\/haematol.2014.109892","article-title":"Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia","volume":"100","author":"Niemeyer","year":"2015","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.semcancer.2017.10.011_bib0490","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2006-09-046649","article-title":"Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations","volume":"109","author":"Matsuda","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.semcancer.2017.10.011_bib0495","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1182\/blood-2007-09-111831","article-title":"Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations","volume":"111","author":"Flotho","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semcancer.2017.10.011_bib0500","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sj.leu.2402407","article-title":"Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group","volume":"16","author":"Manabe","year":"2002","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.semcancer.2017.10.011_bib0505","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1182\/blood-2013-03-491589","article-title":"Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study","volume":"122","author":"Locatelli","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semcancer.2017.10.011_bib0510","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/mpo.2950180411","article-title":"Juvenile chronic myelocytic leukemia: experience with intensive combination chemotherapy","volume":"18","author":"Festa","year":"1990","journal-title":"Med. Pediatr. Oncol."},{"issue":"6","key":"10.1016\/j.semcancer.2017.10.011_bib0515","first-page":"1111","article-title":"Juvenile myelomonocytic leukemia: analyses of treatment results in the EORTC Children's Leukemia Cooperative Group (CLCG)","volume":"18","author":"Lutz","year":"1996","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"10.1016\/j.semcancer.2017.10.011_bib0520","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1365-2141.2005.05489.x","article-title":"Chimaerism analyses and subsequent immunological intervention after stem cell transplantation in patients with juvenile myelomonocytic leukaemia","volume":"129","author":"Yoshimi","year":"2005","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.semcancer.2017.10.011_bib0525","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/pbc.24259","article-title":"Outcomes of immunological interventions for mixed chimerism following allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia","volume":"60","author":"Inagaki","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2017.10.011_bib0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pbc.24294","article-title":"Treatment of disease recurrence after allogeneic hematopoietic stem cell transplantation in children with juvenile myelomonocytic leukemia: a great challenge still to be won","volume":"60","author":"Locatelli","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2017.10.011_bib0535","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/petr.12061","article-title":"Increased risk of gastrointestinal acute GVHD following the addition of melphalan to busulfan\/cyclophosphamide conditioning","volume":"17","author":"Martensson","year":"2013","journal-title":"Pediatr. Transplant."},{"issue":"3","key":"10.1016\/j.semcancer.2017.10.011_bib0540","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bbmt.2013.11.027","article-title":"Fludarabine and exposure-targeted busulfan compares favorably with busulfan\/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity","volume":"20","author":"Bartelink","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"76","key":"10.1016\/j.semcancer.2017.10.011_bib0545","doi-asserted-by":"crossref","first-page":"76ra27","DOI":"10.1126\/scitranslmed.3001069","article-title":"A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice","volume":"3","author":"Lyubynska","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2017.10.011_bib0550","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1172\/JCI63193","article-title":"Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice","volume":"123","author":"Chang","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.semcancer.2017.10.011_bib0555","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/pbc.25575","article-title":"A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: a Children's Oncology Group phase 1 consortium study (ADVL1011)","volume":"62","author":"Loh","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"issue":"10","key":"10.1016\/j.semcancer.2017.10.011_bib0560","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3324\/haematol.2015.136002","article-title":"Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency","volume":"101","author":"Sachs","year":"2016","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.semcancer.2017.10.011_bib0565","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1172\/JCI74182","article-title":"Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm","volume":"124","author":"Kong","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.semcancer.2017.10.011_bib0570","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/ng.2698","article-title":"Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia","volume":"45","author":"Sakaguchi","year":"2013","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.semcancer.2017.10.011_bib0575","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/ng.3420","article-title":"Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network","volume":"47","author":"Caye","year":"2015","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.semcancer.2017.10.011_bib0580","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/ng.3400","article-title":"The genomic landscape of juvenile myelomonocytic leukemia","volume":"47","author":"Stieglitz","year":"2015","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.semcancer.2017.10.011_bib0585","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.2009.24.4426","article-title":"Gene expression-based classification as an independent predictor of clinical outcome in juvenile myelomonocytic leukemia","volume":"28","author":"Bresolin","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.semcancer.2017.10.011_bib0590","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2141.2005.05412.x","article-title":"Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia","volume":"129","author":"Johan","year":"2005","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.semcancer.2017.10.011_bib0595","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1365-2141.2005.05392.x","article-title":"Methylation status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia","volume":"128","author":"Hasegawa","year":"2005","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.semcancer.2017.10.011_bib0600","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.leukres.2008.09.036","article-title":"PTEN deficiency is a common defect in juvenile myelomonocytic leukemia","volume":"33","author":"Liu","year":"2009","journal-title":"Leuk. Res."},{"issue":"18","key":"10.1016\/j.semcancer.2017.10.011_bib0605","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1182\/blood-2010-08-298968","article-title":"Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia (JMML) with poor outcome","volume":"117","author":"Olk-Batz","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.semcancer.2017.10.011_bib0610","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.4161\/epi.29941","article-title":"RASA4 undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia","volume":"9","author":"Poetsch","year":"2014","journal-title":"Epigenetics"},{"issue":"2","key":"10.1016\/j.semcancer.2017.10.011_bib0615","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/15592294.2016.1145327","article-title":"Epigenetic silencing of AKAP12 in juvenile myelomonocytic leukemia","volume":"11","author":"Wilhelm","year":"2016","journal-title":"Epigenetics"},{"issue":"12","key":"10.1016\/j.semcancer.2017.10.011_bib0620","doi-asserted-by":"crossref","first-page":"e0145394","DOI":"10.1371\/journal.pone.0145394","article-title":"Aberrant DNA methylation is associated with a poor outcome in juvenile myelomonocytic leukemia","volume":"10","author":"Sakaguchi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2017.10.011_bib0625","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13148-016-0216-3","article-title":"CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia","volume":"8","author":"Fluhr","year":"2016","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.semcancer.2017.10.011_bib0630","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02177-w","article-title":"RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia","author":"Lipka","year":"2017","journal-title":"Nat. Commun."},{"issue":"15","key":"10.1016\/j.semcancer.2017.10.011_bib0635","doi-asserted-by":"crossref","first-page":"8681","DOI":"10.1073\/pnas.96.15.8681","article-title":"CpG island methylator phenotype in colorectal cancer","volume":"96","author":"Toyota","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.semcancer.2017.10.011_bib0640","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1158\/0008-5472.828.65.3","article-title":"CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas","volume":"65","author":"Abe","year":"2005","journal-title":"Cancer Res."},{"issue":"7489","key":"10.1016\/j.semcancer.2017.10.011_bib0645","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature13108","article-title":"Epigenomic alterations define lethal CIMP-positive ependymomas of infancy","volume":"506","author":"Mack","year":"2014","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.semcancer.2017.10.011_bib0650","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1182\/blood-2008-12-195693","article-title":"Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7","volume":"113","author":"Furlan","year":"2009","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.semcancer.2017.10.011_bib0655","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1182\/blood-2015-01-619734","article-title":"Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group","volume":"125","author":"Cseh","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semcancer.2017.10.011_bib0660","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/sj.leu.2404537","article-title":"Second allogeneic hematopoietic stem cell transplantation (HSCT) results in outcome similar to that of first HSCT for patients with juvenile myelomonocytic leukemia","volume":"21","author":"Yoshimi","year":"2007","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.semcancer.2017.10.011_bib0665","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/sj.leu.2403721","article-title":"Donor leukocyte infusion after hematopoietic stem cell transplantation in patients with juvenile myelomonocytic leukemia","volume":"19","author":"Yoshimi","year":"2005","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.semcancer.2017.10.011_bib0670","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.semcancer.2017.10.011_bib0675","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/leu.2014.44","article-title":"BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies","volume":"28","author":"Bogenberger","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2017.10.011_bib0680","first-page":"1","article-title":"Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies","author":"Grant","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.semcancer.2017.10.011_bib0685","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/leu.2016.275","article-title":"Isocitrate dehydrogenase mutations in myeloid malignancies","volume":"31","author":"Medeiros","year":"2017","journal-title":"Leukemia"},{"issue":"28","key":"10.1016\/j.semcancer.2017.10.011_bib0690","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","article-title":"Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3","volume":"28","author":"Fischer","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2017.10.011_bib0695","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/leu.2015.346","article-title":"The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3\/ITD acute myeloid leukemia cells","volume":"30","author":"Chang","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.semcancer.2017.10.011_bib0700","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ajh.23924","article-title":"Phase I\/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"90","author":"Strati","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.semcancer.2017.10.011_bib0705","doi-asserted-by":"crossref","first-page":"34","DOI":"10.18632\/oncotarget.106","article-title":"Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome","volume":"1","author":"Raffoux","year":"2010","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.semcancer.2017.10.011_bib0710","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00277-016-2681-3","article-title":"Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy","volume":"95","author":"Wu","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.semcancer.2017.10.011_bib0715","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s12885-015-1432-5","volume":"15","author":"Grishina","year":"2015","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2017.10.011_bib0720","first-page":"40","article-title":"Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes","volume":"8","author":"Cogle","year":"2010","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2017.10.011_bib0725","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/bmt.2009.134","article-title":"5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation","volume":"45","author":"Field","year":"2010","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"10.1016\/j.semcancer.2017.10.011_bib0730","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/bmt.2011.86","article-title":"Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome","volume":"47","author":"Kim","year":"2012","journal-title":"Bone Marrow Transplant."},{"issue":"8","key":"10.1016\/j.semcancer.2017.10.011_bib0735","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.bbmt.2012.01.009","article-title":"Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS","volume":"18","author":"Gerds","year":"2012","journal-title":"Biol. Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.semcancer.2017.10.011_bib0740","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/ejh.12038","article-title":"Response to pretransplant hypomethylating agents influences the outcome of allogeneic hematopoietic stem cell transplantation in adults with myelodysplastic syndromes","volume":"90","author":"Yahng","year":"2013","journal-title":"Eur. J. Haematol."},{"issue":"5","key":"10.1016\/j.semcancer.2017.10.011_bib0745","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s12185-014-1549-3","article-title":"Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes","volume":"99","author":"Kim","year":"2014","journal-title":"Int. J. Hematol."},{"issue":"6","key":"10.1016\/j.semcancer.2017.10.011_bib0750","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.bbmt.2014.02.008","article-title":"Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome","volume":"20","author":"Nishihori","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"1","key":"10.1016\/j.semcancer.2017.10.011_bib0755","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbmt.2015.08.031","article-title":"Treatment with hypomethylating agents before allogeneic stem cell transplant improves progression-Free survival for patients with chronic myelomonocytic leukemia","volume":"22","author":"Kongtim","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"9","key":"10.1016\/j.semcancer.2017.10.011_bib0760","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.bbmt.2016.05.026","volume":"22","author":"Potter","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"7","key":"10.1016\/j.semcancer.2017.10.011_bib0765","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdx154","article-title":"Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study","volume":"28","author":"Voso","year":"2017","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.semcancer.2017.10.011_bib0770","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/bmt.2009.355","article-title":"Azacytidine treatment after discontinuation of immunosuppressants in patients with myelodysplastic syndrome and relapse after allo-SCT at a single center","volume":"45","author":"Kim","year":"2010","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"10.1016\/j.semcancer.2017.10.011_bib0775","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bbmt.2010.10.008","article-title":"5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation","volume":"17","author":"Bolanos-Meade","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"7","key":"10.1016\/j.semcancer.2017.10.011_bib0780","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/bmt.2012.256","article-title":"Azacitidine in the treatment of extramedullary relapse of AML after allogeneic hematopoietic cell transplantation","volume":"48","author":"Antar","year":"2013","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"10.1016\/j.semcancer.2017.10.011_bib0785","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/bmt.2013.233","article-title":"Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT","volume":"49","author":"Tessoulin","year":"2014","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"10.1016\/j.semcancer.2017.10.011_bib0790","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1097\/MPH.0000000000000042","article-title":"Azacitidine in the treatment of pediatric therapy-related myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation","volume":"36","author":"Inoue","year":"2014","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.semcancer.2017.10.011_bib0795","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.transproceed.2016.01.078","article-title":"Azacitidine use after allogeneic stem cell transplantation-Results from the polish adult leukemia group","volume":"48","author":"Drozd-Sokolowska","year":"2016","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.semcancer.2017.10.011_bib0800","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2016.07.010","article-title":"Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation","volume":"49","author":"Ghobadi","year":"2016","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.semcancer.2017.10.011_bib0805","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.bbmt.2016.10.016","article-title":"Factors determining responses to azacitidine in patients with myelodysplastic syndromes and acute myeloid leukemia with early post-Transplantation relapse: a prospective trial","volume":"23","author":"Woo","year":"2017","journal-title":"Biol. Blood Marrow Transplant."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X17301050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X17301050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:38:59Z","timestamp":1760917139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X17301050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":161,"alternative-id":["S1044579X17301050"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2017.10.011","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2017.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}